All In Biotech

Drug Trial Radar · NCT05490732

Pharmacokinetic Modeling of Methadone

Pharmacokinetic Population Modeling of Methadone in Patients Managed for Opioid Opioid Addiction

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 23, 2024

Primary completion

Apr 1, 2025

Study completion Sep 1, 2025

Sponsor

Lead sponsor
University Hospital, MontpellierAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The management of patients with opioid addiction is a challenge insofar as many distractors or variability factors can interfere with the control of the addiction, whether they are psychological, psychiatric, environmental, pharmacokinetic or pharmacodynamic. Understanding this variability is potentially to be able to adjust a priori a dosage and to identify the factors of clinical response. Few population pharmacokinetic models exist for methadone and they generally concern the management of pain in palliative care patients or the management of opioid withdrawal syndrome in neonates. The hypothesis is therefore that the creation of such a model would make it possible to reduce patients' withdrawal periods, to set a target for plasma concentrations with a view to reducing dosages, and to empower the patient in his choice to monitor blood concentrations facilitated by a minimally invasive sampling device.

Conditions

  • Toxicomania

Interventions

  • Blood samplingBiological

    Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24. For each one, one microsampling and one venipuncture

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak concentration (Cmax)Time frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU de Montpellier

    Montpellier, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.